Deva Holding AS Cash Flow Conversion Efficiency
Deva Holding AS cash flow conversion efficiency. Based on the latest financial reports, Deva Holding AS (DEVA) has a cash flow conversion efficiency ratio of 0.058x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (TL1.53 Billion ≈ $34.34 Million USD) by net assets (TL26.48 Billion ≈ $593.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Deva Holding AS (2005–2024)
Cash flow conversion efficiency of Deva Holding AS from 2005 to 2024. This chart illustrates how Deva Holding AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View DEVA stock price for real-time trading data and today's change.
Deva Holding AS Cash Flow Conversion Ratio Explained
Deva Holding AS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Deva Holding AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Deva Holding AS ranked by their cash flow conversion efficiency. Also see market cap of Deva Holding AS for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bourrelier Group SA
PA:ALBOU
|
0.072x |
|
BK Technologies Inc
NYSE MKT:BKTI
|
0.067x |
|
M3-Brigade Acquisition V Corp. Class A Ordinary shares
NASDAQ:MBAV
|
-0.001x |
|
Launch Two Acquisition Corp. Class A Ordinary Shares
NASDAQ:LPBB
|
0.000x |
|
Bsm Chemical Co Ltd
SHE:300796
|
0.056x |
|
WONIK Materials Co.Ltd
KQ:104830
|
0.029x |
|
Guangdong Dcenti Auto-Parts Stock Ltd Co
SHG:603335
|
0.088x |
|
Biofarm Bucure
RO:BIO
|
0.052x |
Annual Cash Flow Conversion Efficiency for Deva Holding AS (2005–2024)
The table below shows the annual cash flow conversion efficiency of Deva Holding AS from 2005 to 2024. Review Deva Holding AS free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | TL20.81 Billion ≈ $466.11 Million |
TL5.07 Billion ≈ $113.50 Million |
0.243x | -27.39% |
| 2023-12-31 | TL21.34 Billion ≈ $478.04 Million |
TL7.16 Billion ≈ $160.30 Million |
0.335x | +61.80% |
| 2022-12-31 | TL3.94 Billion ≈ $88.17 Million |
TL815.91 Million ≈ $18.27 Million |
0.207x | -54.69% |
| 2021-12-31 | TL2.73 Billion ≈ $61.10 Million |
TL1.25 Billion ≈ $27.95 Million |
0.457x | +15.74% |
| 2020-12-31 | TL1.63 Billion ≈ $36.61 Million |
TL645.98 Million ≈ $14.47 Million |
0.395x | -7.66% |
| 2019-12-31 | TL1.03 Billion ≈ $23.09 Million |
TL441.24 Million ≈ $9.88 Million |
0.428x | +143.91% |
| 2018-12-31 | TL746.41 Million ≈ $16.72 Million |
TL130.98 Million ≈ $2.93 Million |
0.175x | -4.20% |
| 2017-12-31 | TL605.09 Million ≈ $13.55 Million |
TL110.84 Million ≈ $2.48 Million |
0.183x | -49.88% |
| 2016-12-31 | TL512.85 Million ≈ $11.49 Million |
TL187.44 Million ≈ $4.20 Million |
0.365x | +86.96% |
| 2015-12-31 | TL453.11 Million ≈ $10.15 Million |
TL88.58 Million ≈ $1.98 Million |
0.195x | +56.38% |
| 2014-12-31 | TL411.91 Million ≈ $9.23 Million |
TL51.49 Million ≈ $1.15 Million |
0.125x | +0.69% |
| 2013-12-31 | TL403.05 Million ≈ $9.03 Million |
TL50.04 Million ≈ $1.12 Million |
0.124x | +618.95% |
| 2012-12-31 | TL378.63 Million ≈ $8.48 Million |
TL6.54 Million ≈ $146.43K |
0.017x | -67.04% |
| 2005-12-31 | TL114.50 Million ≈ $2.56 Million |
TL6.00 Million ≈ $134.34K |
0.052x | -- |
About Deva Holding AS
Deva Holding A.S. manufactures, markets, and sells pharmaceutical products in Turkey. The company offers antineoplastic and immunomodulating agents; dermatological products; sysyemic hormanal preparations; anti-infective and antiparasitic products for systemic use; food supplements; and electrolyte solutions. It also provides products in the areas of urogenital system and sex hormones, blood and … Read more